Prof David GerrardProfessor of Sport and Exercise Medicine
Dunedin School of Medicine
10:45 - 11:10 Update on Doping in Sport: Life after Lance Armstrong
Biological variables over time
Indirect “doping” detection
“non-physiological variance”
Blood and steroid modules
Fundamental principle of profiling (ABP)
A marker of blood doping – Haemoglobin
The athlete is their own reference point
Subsequent values compared with normal physiological response
p.14
Legitimises use of banned substance
Prioritises health of patient
Requires physician compliance
Diagnostic criteria
Chronic inflammatory bowel disease
Peri/post-operative management
Hypogonadism
ADD/ADHD
Acute asthma
Type-1 diabetes
• Inhibitor of fatty acid oxidation
• 1970 Latvia
• Indicated for “anti-ischaemia” effects
• Uses: angina, myocardial infarction
• Not approved by FDA
• 2010 clinical trial “…significant increase in exercise tolerance…”
• Monitored by WADA throughout 2015
• Considered to be misused for performance-enhancing effects
• Shushapova
anti-”grunting”
• Saccharinopova low cal
• Supernovapova
multivitamin supplement/electrolyte replacement
“…our professional obligations to patients who also happen to be elite athletes, are subject to the provisions of the WADA Code.”